Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: A gynecologic oncology group study

Gynecologic Oncology

Volumn 99, Issue 2, 2005, Pages 339-342

  Long III, Harry J ^a   Blessing, John A ^b   Sorosky, Joel ^c,d  

^a Mayo Clinic   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d HARTFORD HOSPITAL   (United States)

Author keywords

Cisplatin; Dacarbazine; Doxorubicin; Mitomycin; Uterine leiomyosarcoma

Indexed keywords

CISPLATIN; CORTICOSTEROID; CREATININE; DACARBAZINE; DIPHENHYDRAMINE; DOXORUBICIN; MITOMYCIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; GYNECOLOGIC CANCER; HUMAN; INFECTION; LEIOMYOSARCOMA; LUNG DISEASE; LUNG INFILTRATE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PERFORMANCE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTE; THROMBOCYTOPENIA; TRANSFUSION; TREATMENT OUTCOME; UREMIA; UTERUS CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DACARBAZINE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; LEIOMYOSARCOMA; LEUKOPENIA; MIDDLE AGED; MITOMYCIN; UTERINE NEOPLASMS;

EID: 27144519657     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.06.002     Document Type: Article

References (11)

1. G.A. Omura, F.J. Major, and J.A. Blessing A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas Cancer 52 1993 626 632
2. J.T. Thigpen, J.A. Blessing, J. Beecham, H.D. Homesley, and E. Yordan Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study J. Clin. Oncol. 9 1991 1962 1966
3. G.P. Sutton, J.A. Blessing, R.J. Barrett, and R. McGhee Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study Am. J. Obstet. Gynecol. 166 1992 556 559
4. S. Rockwell, K.A. Kennedy, and A.C. Sartorelli Mitomycin-C as a prototype bioreductive alkylating agent: in vitro studies of metabolism and cytotoxicity Int. J. Radiat. Biol. Phys. 8 1982 753 755
5. R.E. Durand Synergism of cisplatin and mitomycin-C in sensitive and resistant subpopulations of a tumor model Int. J. Cancer 44 1989 911 917
6. M. Zapulski, B. Metch, and S. Balcerzak Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study J. Natl. Cancer Inst. 83 1991 926 932
7. J.H. Edmonson, J.A. Blessing, J.A. Cosin, D.S. Miller, D.E. Cohn, and J. Rotmensch Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study Gynecol. Oncol. 85 2002 507 510
8. S. Vadhan-Raj, H.E. Broxmeyer, and W.N. Hittelman Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level J. Clin. Oncol. 10 8 1992 1266 1277
9. H.E. Broxmeyer, L. Benninger, S.R. Patel, R.S. Benjamin, and S. Vadhan-Raj Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor Exp. Hematol. 22 1 1994 100 102
10. J.H. Edmonson, L.C. Hartmann, and H.J. Long Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin Cancer 70 1992 2529 2539
11. J.H. Edmonson, R.S. Marks, J.C. Buckner, and M.R. Mahoney Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus sargramostim between patients with advanced malignant gastrointestinal stromal tumors plus patients with other advanced leiomyosarcomas Cancer Invest. 20 2002 605 612